Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,582.55
(
-0.05%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 233259

Tuesday, 09/29/2020 10:04:00 AM

Tuesday, September 29, 2020 10:04:00 AM

Post# of 257443
MYOV—(-23%)—misses secondary endpoint in CSPC phase-3 comparing relugolix to Lupron:

https://www.globenewswire.com/news-release/2020/09/29/2100606/0/en/Myovant-Sciences-Announces-Results-of-Additional-Secondary-Endpoint-of-Castration-Resistance-Free-Survival-from-Phase-3-HERO-Study-of-Relugolix-in-Advanced-Prostate-Cancer.html

This trial previously met its primary endpoint, and relugolix is under FDA review with a 12/20/20 PDUFA date.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today